Jerry, you’re invoking a 2012 reverse split like it’s a prophecy rather than a chapter in history. That split did work, NWBO successfully uplisted to NASDAQ and closed a public offering. What failed wasn’t the mechanism; it was sustained investor suppression, structural OTC market manipulation, and an unlevel playing field for a clinical-stage biotech.
Then there was the infamous German trial scare. In August 2015 the European database listed a “temporary halt” in patient screening for DCVax-L in Germany. That triggered panic, but reality was far less dramatic. The trial continued without interruption, treatment proceeded as usual. Only the screening of new patients paused, as the company finalized paperwork for regulatory review.
What confused everyone was pseudoprogression. The vaccine’s immune mechanism often causes inflammation and edema that mimic tumor growth on MRI. That’s not failure, it’s evidence the immune system is doing its job. Some of the patients flagged as progressing were actually long-term survivors. That insight helped shift the field’s framework toward overall survival, not progression-free survival.
Then came the breakthrough. NWBO published its Phase III results in JAMA Oncology on November 17, 2022. The median overall survival in newly diagnosed GBM patients reached 19.3 months versus 16.5 in controls, with 60-month survival of 13?% versus 5.7?%. In the recurrent setting, survival climbed to 13.2 months versus 7.8, with survival rates at 24 and 30 months more than doubling.
These results were even more extraordinary considering the structure of the trial itself. This was not an academic or subsidized program. It was conducted under real-world conditions in which all patients received the full standard of care, surgery, radiation, and chemotherapy, before receiving DCVax. That context is critical. These were immune systems already beaten down by conventional therapy. And still, the vaccine demonstrated survival extension and long-term benefit.
Now fast forward to the Bosch presentation, where NWBO’s Chief Technical Officer detailed how booster-class agents can be combined with DCVax to enhance dendritic cell maturation. That means rather than waiting for a patient’s immune system to determine responsiveness, DCVax could be configured to induce responsiveness, essentially programming patients to become responders. Add to that the Roswell cytokine toolkit, which includes supercharged agents capable of reprogramming the tumor microenvironment, and you arrive at the possibility of sustained immunity with just one or two doses. This is not speculative. It is the architecture of a platform built for durability, scalability, and immune system reeducation.
Those results rewrote cancer immunotherapy rules. Regulators now favor OS-based validation, and DCVax-L’s success set that precedent. Academic centers across the globe helped validate the method for next to no cost through compassionate use and academic partnerships. That was smart execution, not reckless spending.
Now let that sink in. Once approved, DCVax-L can achieve tissue-agnostic and even lysate-agnostic labeling. That means the platform is not constrained by tumor type or antigen source; it becomes a programmable immune system. That rare architecture transforms it into a category partner or acquirer would want built, not broken.
Now consider RevImmune. Injecting IL-7 into the immune equation supplements DCVax by restoring T cell youth, naïve cascades, and memory maintenance. That merger isn’t dilution. It’s exponential growth. It readies NWBO for uplisting without a reverse split, which was confirmed in 2022 when Linda Powers said they were evaluating uplisting “without having to do a reverse split.”
And yes, NWBO delisted from NASDAQ in December 2016 voluntarily, retaining the right to return once structural milestones are hit. That gives them a clean, expedited path to relist, with real capabilities now backing the story.
So if a CUSIP change appears now, don’t fear dilution. Expect structural scale and immune system composability. The ticker may change. The mission already didn’t.
RevImmune. Has a nice ring, doesn’t it?
Bullish
Market Data 
Markets 
